GeneDx today announced Biogen, Praxis Precision Medicines and Stoke Therapeutics as the founding partners to its Patient Access Program for epilepsy.

NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, Inc. (Nasdaq: IMDX), (“iMDx”), today announced a positive strategic update and novel registry that will serve to ...

GeneDx leverages a vast rare disease database and advanced genomic testing, offering superior insights. Read why I am bullish about WGS stock.

The ability of large language models (LLMs) to identify access to germline genetic testing from unstructured text remains unknown. The Department of Veterans Affairs (VA) assessed access in Veterans ...

Post this Blood-based Nodify Lung testing, comprised of the Nodify CDT® and Nodify XL2® tests, addresses a significant unmet need by assessing the risk of cancer in patients with lung nodules.

Patients and doctors need to have access to them and patient privacy must be protected at the same time, the author writes.

The Patient Access Program aims to address these challenges by increasing access to whole exome sequencing for pediatric epilepsy patients.